Greg Keenan

Chief Medical Officer

Greg Keenan, MD, joined Aurinia in 2023 as Chief Medical Officer. Dr. Keenan is an experienced physician who has played key roles in Phase 1 through Phase 4 clinical development of over 19 products, including small and large molecules as well as gene therapies across numerous therapeutic areas as well as numerous orphan and rare diseases. 

Most recently, he was the Chief Medical Officer at ValenzaBio, an early-stage biotech company developing biologic treatments for a variety of autoimmune and inflammatory diseases.  Prior to that he was Senior Vice President, Global Head of Medical and Drug Safety at Avrobio, a gene therapy company. Previously he served as Vice President, U.S., Medical Affairs and Head Medical Officer at AstraZeneca, which he joined following the company’s acquisition of Medimmune.  Earlier, he held roles of increasing responsibility at Human Genome Sciences Inc., and at Johnson and Johnson’s Centocor subsidiary.

Dr. Keenan began his career as a rheumatologist in academia, holding appointments at The Hospital of the University of Pennsylvania and the Children’s Hospital of Pennsylvania. He completed fellowships in pediatric and adult rheumatology at the University of Pennsylvania after having completed his residency in medicine/pediatrics at the LA County/University of Southern California Medical Center. Dr. Keenan holds an M.D. from Albany Medical College and a B.A. from Colby College.